NCT02103894

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Molecular NeuroImaging · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to assess \[18F\]MNI-777 PET imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: Alzheimer's Disease (AD),Parkinson's disease (PD) Progressive Supranuclear Palsy (PSP), chronic traumatic encephalopathy (CTE) and Frontal Temporal Dementia (FTD) and age- and gender-matched healthy subjects.

Conditions

• Alzheimer's Disease (AD)
• Parkinson's Disease (PD)
• Chronic Traumatic Encephalopathy (CTE)
• Progressive Supranuclear Palsy (PSP)
• Frontal Temporal Dementia (FTD)
• Pick's Disease
• Tauopathies

Interventions

Type	Name	Description
DRUG	[18F]T807 ([18F]MNI-777)	All enrolled subjects will undergo an \[18F\]MNI-777 PET imaging visit. For individuals with AD or CTE, \[18F\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by \[18F\]florbetapir imaging) and tau protein uptake (measured by \[18F\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \[123I\]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.

Timeline

• Start date: 2014-02-01
• Primary completion: 2016-08-01
• Completion: 2016-09-01
• First posted: 2014-04-04
• Last updated: 2016-12-16

Locations

1 site across 1 country: United States